Last reviewed · How we verify
D-Loxiglumide (DEXLOXIGLUMIDE)
D-Loxiglumide (generic name: DEXLOXIGLUMIDE) is a dexloxiglumide drug. It is currently in Phase 3 development.
Dexloxiglumide works by binding to the cholecystokinin receptor type A, which is involved in regulating digestive processes.
D-Loxiglumide is a small molecule that acts as an antagonist to the cholecystokinin A receptor. It is classified as an antagonist and works by blocking the cholecystokinin A receptor.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | DEXLOXIGLUMIDE |
|---|---|
| Drug class | dexloxiglumide |
| Target | Cholecystokinin receptor type A |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Imagine your body has a system to control digestion. Dexloxiglumide helps by blocking a specific receptor that sends signals to slow down digestion. This can help with conditions related to digestive issues, but more research is needed to confirm its effectiveness.
Approved indications
Common side effects
Key clinical trials
- The Safety and Efficacy of Dexloxiglumide for the Relief of Symptoms of Functional Dyspepsia. (PHASE2)
- DARWIN Study: A Randomization/Withdrawal Efficacy Study of Dexloxiglumide in Constipation-Predominant Irritable Bowel Syndrome (C-IBS) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- D-Loxiglumide CI brief — competitive landscape report
- D-Loxiglumide updates RSS · CI watch RSS
Frequently asked questions about D-Loxiglumide
What is D-Loxiglumide?
How does D-Loxiglumide work?
What is the generic name of D-Loxiglumide?
What drug class is D-Loxiglumide in?
What development phase is D-Loxiglumide in?
What does D-Loxiglumide target?
Related
- Drug class: All dexloxiglumide drugs
- Target: All drugs targeting Cholecystokinin receptor type A
- Therapeutic area: All drugs in Gastroenterology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing